{"id":37031,"date":"2025-07-09T15:30:30","date_gmt":"2025-07-09T07:30:30","guid":{"rendered":"https:\/\/flcube.com\/?p=37031"},"modified":"2025-07-09T15:30:31","modified_gmt":"2025-07-09T07:30:31","slug":"adagene-collaborates-with-conjugatebio-to-develop-bispecific-antibody-drug-conjugates","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37031","title":{"rendered":"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates"},"content":{"rendered":"\n

China-based Adagene Inc. (NASDAQ: ADAG<\/a>) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to jointly develop bispecific antibody drug conjugates (ADCs). The partnership involves an undisclosed amount of upfront payment, milestone payments, and tiered royalties. Adagene will contribute its proprietary antibodies while retaining all rights to these antibodies for non-ADC applications.<\/p>\n\n\n\n

Adagene’s Capabilities<\/strong>
Adagene, a clinical-stage biopharma company with platform-driven discovery capabilities, focuses on developing novel antibody-based cancer immunotherapies. Its tripartite platform comprises NEObody, SAFEbody, and POWERbody, along with a unique pipeline addressing unmet needs in oncology.<\/p>\n\n\n\n

ConjugateBio’s Expertise<\/strong>
ConjugateBio specializes in developing first-in-class bispecific ADCs for solid tumors. The company leverages third-generation linker-payload technologies to advance its therapeutic candidates.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to…<\/p>\n","protected":false},"author":1,"featured_media":37033,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[180,35,4059,973],"class_list":["post-37031","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adagene","tag-adc-xdc","tag-conjugatebio","tag-nasdaq-adag"],"yoast_head":"\nAdagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to jointly develop bispecific antibody drug conjugates (ADCs). The partnership involves an undisclosed amount of upfront payment, milestone payments, and tiered royalties. Adagene will contribute its proprietary antibodies while retaining all rights to these antibodies for non-ADC applications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37031\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates\" \/>\n<meta property=\"og:description\" content=\"China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to jointly develop bispecific antibody drug conjugates (ADCs). The partnership involves an undisclosed amount of upfront payment, milestone payments, and tiered royalties. Adagene will contribute its proprietary antibodies while retaining all rights to these antibodies for non-ADC applications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37031\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T07:30:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-09T07:30:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0911.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37031#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37031\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates\",\"datePublished\":\"2025-07-09T07:30:30+00:00\",\"dateModified\":\"2025-07-09T07:30:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37031\"},\"wordCount\":127,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37031#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0911.webp\",\"keywords\":[\"Adagene\",\"ADC \\\/ XDC\",\"ConjugateBio\",\"NASDAQ: ADAG\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37031#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37031\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37031\",\"name\":\"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37031#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37031#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0911.webp\",\"datePublished\":\"2025-07-09T07:30:30+00:00\",\"dateModified\":\"2025-07-09T07:30:31+00:00\",\"description\":\"China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to jointly develop bispecific antibody drug conjugates (ADCs). The partnership involves an undisclosed amount of upfront payment, milestone payments, and tiered royalties. Adagene will contribute its proprietary antibodies while retaining all rights to these antibodies for non-ADC applications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37031#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37031\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37031#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0911.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0911.webp\",\"width\":1080,\"height\":608,\"caption\":\"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37031#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates - Insight, China's Pharmaceutical Industry","description":"China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to jointly develop bispecific antibody drug conjugates (ADCs). The partnership involves an undisclosed amount of upfront payment, milestone payments, and tiered royalties. Adagene will contribute its proprietary antibodies while retaining all rights to these antibodies for non-ADC applications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37031","og_locale":"en_US","og_type":"article","og_title":"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates","og_description":"China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to jointly develop bispecific antibody drug conjugates (ADCs). The partnership involves an undisclosed amount of upfront payment, milestone payments, and tiered royalties. Adagene will contribute its proprietary antibodies while retaining all rights to these antibodies for non-ADC applications.","og_url":"https:\/\/flcube.com\/?p=37031","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-09T07:30:30+00:00","article_modified_time":"2025-07-09T07:30:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0911.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37031#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37031"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates","datePublished":"2025-07-09T07:30:30+00:00","dateModified":"2025-07-09T07:30:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37031"},"wordCount":127,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37031#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0911.webp","keywords":["Adagene","ADC \/ XDC","ConjugateBio","NASDAQ: ADAG"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37031#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37031","url":"https:\/\/flcube.com\/?p=37031","name":"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37031#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37031#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0911.webp","datePublished":"2025-07-09T07:30:30+00:00","dateModified":"2025-07-09T07:30:31+00:00","description":"China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to jointly develop bispecific antibody drug conjugates (ADCs). The partnership involves an undisclosed amount of upfront payment, milestone payments, and tiered royalties. Adagene will contribute its proprietary antibodies while retaining all rights to these antibodies for non-ADC applications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37031#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37031"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37031#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0911.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0911.webp","width":1080,"height":608,"caption":"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37031#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0911.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37031"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37031\/revisions"}],"predecessor-version":[{"id":37034,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37031\/revisions\/37034"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37033"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}